<DOC>
	<DOCNO>NCT02235233</DOCNO>
	<brief_summary>This study design investigate effect NASH ( non-alcoholic steatohepatitis ) disposition 99mTechnetium ( Tc ) -mebrofenin relate change 99mTc-mebrofenin disposition difference bile acid profile Fibroscan Fibrosis Score healthy subject compare patient NASH .</brief_summary>
	<brief_title>Effect Non-Alcoholic Steatohepatitis ( NASH ) Pharmacokinetics 99mTechnetium-Mebrofenin</brief_title>
	<detailed_description>This open-label , clinical study male female patient NASH ( n=10 ) healthy volunteer ( n=10 ) race ethnicity investigate effect liver disease pharmacokinetics 99mTechnetium-mebrofenin . The use gamma emitter 99m Tc- label mebrofenin allow real-time assessment hepatic exposure . To determine difference healthy subject patient NASH , blood hepatic concentration analyze non-compartmental analysis . Additionally , serum bile acid sample fibroscan data collect determine whether bile acid profile and/or fibroscan reading different healthy subject patient NASH . Changes 99mTc-mebrofenin correlate patient specific bile acid profile fibroscan data . This study increase understate effect liver disease disposition medication undergo transporter-mediated hepatic clearance .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Technetium Tc 99m mebrofenin</mesh_term>
	<criteria>1 . Healthy subject : define free significant cardiac , pulmonary , gastrointestinal , hepatic , biliary , renal , hematological , neurological psychiatric disease determine history , physical examination clinical laboratory test result . 2 . NASH subject : define recent liver biopsy consistent NASH without cirrhosis ; NAS score &gt; 3 . 3 . Fluent literate English . 4 . Willing able give inform consent prior enter study . 1 . Donation blood within last 30 day . 2 . History significant alcohol abuse ( &gt; 20g/day ) and/or illicit drug use , whether successfully treat . 3 . Inability abstain alcohol 48 hour prior study visit . 4 . Inability fast 8 hour prior study sample collection . 5 . Women pregnant , try become pregnant , breast feeding . 6 . Use drug associated clinical histological picture consistent fatty liver disease NASH 12 consecutive week year prior screening ; include amiodarone , tamoxifen , methotrexate , glucocorticoid , anabolic steroid , tetracycline , estrogens dos great use hormone replacement valproate/valproic acid 7 . Type 2 diabetes treat oral agent metformin ; include secretagogues , thiazolidinediones , alphaglucosidase inhibitor , exenatide pramlintide . 8 . Current recent use bile acid sequestrants , bile acid derivative ( i.e . ursodiol ) fibric acid derivative . 9 . Serum blood glucose read study enrollment &gt; 200 mg/dL . 10 . Current use antioxidant silymarin , vitamin C , glutathione , nonprescribed complementary alternative medication ( include dietary supplement , megadose vitamin , herbal preparation , special tea ) within 30 day prior screen . A multivitamin vitamin E standard dose allow . 11 . Previous liver biopsy demonstrate presence cirrhosis . 12 . Radiologic image consistent cirrhosis portal hypertension . 13 . Evidence decompensated liver disease define follow : serum albumin &lt; 3.2 g/dL , total bilirubin &gt; 1.5 mg/dL , PT/INR &gt; 1.3 time normal screening , history presence ascites , encephalopathy , bleed esophageal varix . 14 . Serum creatinine 2.0 mg/dL great , dialysis , screen . 15 . History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , severe psoriasis , rheumatoid arthritis ) could affect assessment biomarkers ( bile acid inflammation ) . 16 . Primary , secondary extrahepatic malignancy . 17 . History bariatric surgery . 18 . Participation research drug trial , exclusive SyNCH Phase I II trial , within 30 day screen . 19 . BMI &gt; 45 kg/m2 screening ( body weight within 20 % ideal body weight ) . 20 . Inability unwillingness give inform consent abide study protocol . 21 . Estimated weekly strenuous exercise great 4 hour per week . 22 . History evidence illness condition drug therapy would make patient , opinion investigator , unsuitable study ( poorly control psychiatric disease , coronary artery disease , active gastrointestinal condition take drug know interfere bile acid synthesis metabolism metabolism/transport drug ) . 23 . Undergone radiographic procedure ( dental Xrays ) , receive radioactive substance , handle radioactive material conjunction employment within last twelve month . 24 . A history hypersensitivity 99mTcmebrofenin , ultrasound gel , dairy product , excipients . 25 . Consumed caffeine ( coffee , tea , cola , chocolate ) within 24 hour study . 26 . A history tobacco use within 12 month study . 27 . Serology positive Hepatitis B , Hepatitis C HIV screen . 28 . A history gastrointestinal hepatobiliary surgery disorder . Healthy Subjects : 1 . Taking concomitant medication , either prescription nonprescription ( include herbal product overthecounter medication ) , oral contraceptive multivitamin ( woman stabilize hormonal method birth control allow participate ) 2 . History evidence liver disease opinion study investigator . 3 . BMI &gt; 30 kg/m2 screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>